Dare Bioscience notified of Nasdaq delisting risk over equity deficiency
Dare Bioscience was notified by Nasdaq's Listing Qualifications Staff on July 13, 2026, that the company no longer complies with Nasdaq Listing Rule 5550(b) because its Form 10-Q for the period ended March 31, 2026 reported stockholders' equity of less than $2.5 million and, as of that date, the company did not meet alternative requirements of $35 million in market value of listed securities or $500,000 in net income from continuing operations. The company intends to timely request a hearing before a Nasdaq Hearing Panel, which will stay delisting pending the panel's decision.
Key facts
- Notified July 13, 2026 by Nasdaq Listing Qualifications Staff of noncompliance with Rule 5550(b)
- Form 10-Q for period ended March 31, 2026 reported stockholders' equity of less than $2.5 million
- Company did not meet alternative requirements of $35 million in market value of listed securities or $500,000 in net income from continuing operations as of July 13, 2026
- Company intends to timely request a hearing before a Nasdaq Hearing Panel to stay suspension and delisting pending the panel's decision
Why it matters
Dare Bioscience faces potential delisting from Nasdaq unless it can cure the stockholders' equity deficiency or meet alternative listing standards, or persuade the Hearing Panel to grant an extension period to regain compliance.
Share
Derived from 8-K filed 2026-07-17. Not investment advice. View the source filing on SEC.gov →